Raav expression systems for genetic modification of specific capsid proteins

(canceled)

(canceled)

47-49. (canceled)

An rAAV vector comprising a nucleic acid segment modified to express functional VP1 and VP3 capsid proteins substantially in the absence of functional VP2 protein.

(canceled)

An rAAV vector comprising:

• a nucleic acid segment that has been modified to express functional VP1 and VP2 capsid proteins substantially in the absence of functional VP3 protein.

(canceled)

An rAAV vector comprising a nucleic acid segment that has been modified to express functional VP2 and VP3 capsid proteins substantially in the absence of functional VP1 protein.

68-75. (canceled)

A VP2-free rAAV expression system comprising:

• (a) at least a first rAAV vector that comprises at least a first heterologous nucleic acid segment inserted into the capsid sequence region, said segment encoding at least a first heterologous peptide;
• and
• (b) at least a second expression vector that expresses functional VP1 and VP3 capsid proteins substantially in the absence of VP2 protein, or at least a second and a third expression vector that separately express functional VP1 and VP3 capsid proteins, each substantially in the absence of VP2 protein.

77-102. (canceled)

An rAAV vector comprising at least a first mutation in the capsid gene, wherein said mutation substantially reduces or eliminates the affinity of a viral particle comprising said vector for binding to heparin, heparan sulfate, or heparan sulfate proteoglycan.

104-106. (canceled)